Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves Shire's triple-bead ADHD therapy

June 23, 2017 7:11 PM UTC

FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients ages 13 and older. The product consists of 3-component, extended release, single-entity mixed amphetamine...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Shire plc